Disorder Related to Cardiac Transplantation Clinical Trial
Official title:
Assessment of Cardiac Allograft Vasculopathy (CAV) by Optical Coherence Tomography (OCT)
Cardiac allograft vasculopathy (CAV) is characterized by marked intimal proliferation and
concentric vascular thickening and fibrosis. CAV remains the leading cause of late morbidity
and mortality in heart transplant recipients. Optical coherence tomography (OCT) is a new
generation catheter-based modality that acquires images at a spatial resolution of 10-20 μm
which is 10-fold greater than that of intravascular ultrasound (IVUS). OCT is currently the
most sensitive imaging technique for early CAV detection. Recent studies proved that
circulating human leukocyte antigen (HLA) directed donor-specific antibodies correlate with
increased mortality and CAV. Contradiction of scientific results has been reported regarding
increased resting heart rate and development of CAV. Larger prospective studies using more
sensitive CAV detecting methods are required to enhance our understanding. Novel
immunosuppressants, mechanistic target of rapamycin (mTOR) inhibitors, may attenuate CAV
progression and may improve long-term allograft survival owing to favorable coronary
remodeling.
Aim of the study: Use OCT imaging for identification of patients with early rapid progression
of CAV (rapid progressors) and to identify the critical risk factors responsible for CAV
progression. The impact of conventional and heart transplant (HTx) specific risk factors,
such as donor-specific antibodies or rapid heart rate will be studied in a prospective,
national-level cohort study. The implication of OCT results will lead to adjustment of
immunosuppressive therapy in one year after heart transplant to prevent further progression
of the disease in CAV rapid progressors.
Working hypotheses:
1. Patients with rapid progression of cardiac allograft vasculopathy can be identified by
increased titers of donor specific anti-human leukocyte antigen (anti-HLA) and/or
antibodies against major histocompatibility complex (MHC) class I-related chain A (MICA)
antibodies.
2. Specific high-risk characteristics of anti-HLA antibodies can be identified that are
associated with particularly high rate of CAV progression (vascular complement
activation in biopsies, certain HLA haplotypes).
3. Tachycardia in heart transplant recipients represents a risk factor for development of
cardiac allograft vasculopathy.
4. Influence of anti-HLA antibodies and increased heart rate is independent of already
established risk factors of CAV.
Cardiac allograft vasculopathy (CAV) represents the leading cause of late morbidity and
mortality in heart transplant recipients and accounts for a second of all-cause mortality at
3 years. Development of CAV is a complex process involving intimal thickening,
atherosclerosis, thrombosis and vasculitis by histology, but ultimately, intimal hyperplasia
is the predominant cause of lumen narrowing, leading to ischemia and graft failure. In
distinction from general coronary atherosclerosis, which is marked by focal and eccentric
fibrofatty atheroma, CAV affects diffusely the entire coronary vasculature with marked
intimal proliferation and concentric vascular thickening and fibrosis.
Optical coherence tomography (OCT), compared with IVUS, is more sensitive for early detection
of CAV. OCT is a new generation catheter-based modality that acquires images at a spatial
resolution of 10-20 μm which is 10-fold greater than that of IVUS. OCT could obviously
identify the layer of media as a lower-echoic line, which could not be identified by IVUS.
When assessing the quality of an intracoronary structure accurately, OCT seems to have more
potential than IVUS.
The endothelial cells of the cardiac vasculature express human leukocyte antigens (HLA) and
others, such as vimentin and major histocompatibility complex (MHC) class I-related chain A
(MICA), and appear to be primary targets of cell-mediated and humoral immune responses after
heart transplant (HTx). Circulating antibodies mediate rejection through complement
activation and fixation on graft endothelium, thereby predisposing the patient to graft loss,
accelerated cardiac allograft vasculopathy, and death. The rate of allosensitized patients
(patients with circulating antibodies against donor antigens) on waiting lists is increasing
as a consequence of growing numbers of retransplants and assist-device implantations.
Allosensitization is a consequence of exposure to disparate HLA molecules during pregnancy,
blood/platelet transfusions, or after cardiac repairs with homograft material, but may occur
in some patients even without any of these triggers from unknown reasons.
Orthotopic heart transplantation is accompanied by sympathetic and parasympathetic
denervation. The subsequent heart rate is usually higher and the circadian variation is low
due to elimination of the vagus nerve effect. It is known that persistent increase in heart
rate contributes to the pathogenesis of vascular diseases.
AIMS OF THE PROJECT The aim of this study is to use OCT imaging for identification of
patients with early rapid progression of cardiac allograft vasculopathy (rapid progressors)
and to identify the critical risk factors responsible for CAV progression. The impact of
conventional and HTx-specific risk factors, such as donor-specific antibodies (using the most
sensitive methods for its measurement) or rapid heart rate (using repeated Holter monitoring)
will be studied in a prospective, national-level cohort study. The implication of OCT results
will lead to adjustment of immunosuppressive therapy in one year after heart transplant to
prevent further progression of the disease in CAV rapid progressors.
WORKING HYPOTHESES
1. Patients with rapid progression of cardiac allograft vasculopathy can be identified by
increased titers of donor specific anti-HLA and/or MICA antibodies.
2. Specific high-risk characteristics of anti-HLA antibodies can be identified that are
associated with particularly high rate of CAV progression (vascular complement
activation in biopsies, certain HLA haplotypes).
3. Tachycardia in heart transplant recipients represents a risk factor for development of
cardiac allograft vasculopathy.
4. Influence of anti-HLA antibodies and increased heart rate is independent of already
established risk factors of CAV.
STUDY DESIGN Collection of data and blood samples will be performed at the same time as the
patient's regularly scheduled surveillance cardiac catheterization (1 month and 12 months
after heart transplant). Additionally donor-specific anti-HLA antibodies (class I, II) and
MHC complex class I - related chain A (MICA) antibodies will be measured also before heart
transplant and in 6 months after heart transplant during regular follow-ups.
OCT (optical coherency tomography) imaging will be performed at the same time as the
patient's regularly scheduled surveillance cardiac catheterization (1 month and 12 months
after heart transplant). OCT imaging will be performed with the commercially available
second-generation frequency domain Ilumien Optis (St. Jude Medical, St. Paul, MN). The OCT
catheter (Dragonfly Duo) will be advanced over a 0.014-inch coronary guide wire into the
middle segments of all three main arteries (left anterior descending, left circumflex and
right coronary artery) and imaging will be performed by automated pullback with a length 45
mm, with pullback speed 25 mm/sec in high resolution mode (10 frames /mm). OCT examination
will be performed after administration of 200-300 μg of intracoronary nitroglycerin and
simultaneous injection of 14 ml of contrast agent to each artery by power injector through
the guiding catheter. OCT data will be used for 3-D vessel reconstruction done by the fusion
with routine angiography performed in two projections at least 60 degree apart.
The image data acquired from two-plane angiography, can be utilized to accurately reconstruct
the path and orientation of the OCT catheter in 3-D.
The two-plane angiograms are taken immediately prior to the pullback start and cover at least
one heart cycle each. They are used to extract the catheter path automatically along the
expected pullback trajectory by a dynamic programming approach. From the known imaging
geometry, an accurate 3-D model of the catheter path within the respective vessel segment is
generated for end-diastolic heart phase. For OCT acquisition, motorized pullback ensures a
constant pullback speed, thus allowing to assign each OCT image frame a specific location on
the 3-D catheter trajectory model. The relative and absolute orientations of the OCT frames
are determined using previously reported system for establishing the absolute orientation in
3-D on IVUS images. Quantitative data can be derived from the contour data, such as luminal
dimensions and plaque-cap thickness, actually considering the vessel curvature in contrast to
conventional OCT reconstruction systems. The space between adjacent contours is interpolated
to form a volume element. In locations of the plaque cap, integrating over an entire vessel
segment or any part thereof yields the total plaque cap volume enclosed by the inner and
outer cap surfaces.
The OCT examination will be analyzed according to OCT consensus standard definitions. Intima
can be recognized as a uniform signal-rich bright layer and media as a signal-poor darker
layer due to low backscatter. The lumen, intima, and media layers will be traced
automatically with manual correction to obtain average thickness and areas for every frames.
The only segment without any signs of coronary atherosclerosis on coronary angiography will
be used for OCT examination. Following indices will be analyzed:
1. Normalized intimal volume: the sum of intimal cross sectional area (difference between
media area and lumen area) in every frames / pullback length.
2. Normalized lumen volume: the sum of lumen cross sectional area in every frames /
pullback length.
3. Mean intima thickness: the values from all sufficient quality frames will be averaged to
yield average intima thickness.
4. Mean intima-to-media ratio (I/M): Values from all sufficient quality frames will be
averaged to yield average intima thickness, and media thickness. The intima-to-media
ratio (I/M) will be calculated as a ratio of average area of each layer over the whole
pullback. An I/M ratio of more than 1 will be defined as abnormal.
These indices will be compared between baseline and follow-up examinations. After
identification of vascular landmarks corresponding in the two 3-D vessel models, the patient
specific model pairs will be co-registered to correctly match the OCT pullbacks.
OCT baseline and follow-up examinations will be performed in Prague (IKEM hospital) and Brno
(Saint Anna hospital) and data will be send to the core lab in the Iowa Institute for
Biomedical Imaging, The University of Iowa, USA for analysis. Iowa Institute for Biomedical
Imaging is a research centre, which has extensive experience with the evaluation of coronary
atherosclerosis. For the purpose of detailed analysis of the coronary arteries unique
software for creating 3-D reconstructions of coronary arteries based on the fusion of
angiography and optical coherence tomography was developed at this institution. This software
enables exact assessment of plaque and lumen volumes. Software is protected by U.S. patent.
Because of large volume of data and patients in this project, applications of such automated
analytic tools are prerequisite of successful accomplishment.
Mean heart rate will be measured during 24 hour ECG Holter monitoring, which will evaluate
all necessary parameters including its circadian variability. ECG Holter recordings will be
performed in 1 month and in 12 months after heart transplant. In addition to mean 24 hour
heart rate, time and frequency domain components of heart rate variability will be analyzed
to obtain estimate the extent of vagal reinnervation.
Donor-specific anti-HLA antibodies(class I,II) and MHC complex class I - related chain A
(MICA) antibodies will be measured (before heart transplant, 1 month, 6 months and 12 months
after heart transplant). Evaluation of anti-HLA antibodies levels (titers) in the serum of a
patient is performed by fluorescence intensity of formed complexes. Double laser cytometer
Luminex 100 IS 2.3 is used for fluorescence reading. Based on comparison of negative and
positive controls, cut-off is calculated.
Conventional risk factors for CAV will be determined in 1 month and in 12 months after heart
transplant.
Lipid profile (total cholesterol, LDL, HDL and triglycerides) will be measured. Blood
pressure in triplicate will be measured in supine position (1 hour before regular
endomyocardial biopsies). Glycemic control will be quantified by measurements of Hemoglobin
A1 level, plasma glucose. Cytomegalovirus (CMV) status will be measured by immunoglobulin G
(IgG), immunoglobulin M (IgM) titers.
Other monitored parameters will be: 1) the post transplant course and clinical status; the
occurrence of graft dysfunction (echocardiographic monitoring will follow each endomyocardial
biopsy), 2) the occurrence of cellular and/or humoral rejection in endomyocardial biopsies (8
protocolar endomyocardial biopsies within 12 months after heart transplantation), 3) presence
and tissue distribution (vascular/non-vascular) staining for complement fragments C3 and C4
(markers of antibodies-mediated complement activation), 4) the period of cardiac allograft
cold ischemia 5) aetiology of brain death of the donor 6) degree of HLA mismatch between
donor and recipient, 7) blood cytokine levels involved in regulation of humoral immune
response.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02347371 -
Heart Transplant Registry of Városmajor
|
||
| Completed |
NCT00377962 -
Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation
|
Phase 4 |